Szmulewitz, R.Z., Peer, C.J., Ibraheem, A., Martinez, E., Kozloff, M.F., Carthon, B., Harvey, R.D., Fishkin, P., Yong, W.P., Chiong, E., Nabhan, C., Karrison, T., Figg, W.D., Stadler, W.M. and Ratain, M.J. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone with Food versus Standard Dose Abiraterone in Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 36, 1389-1395.
https://doi.org/10.1200/JCO.2017.76.4381

has been cited by the following article:

• TITLE: Evolution of Androgenic Deprivation in Treatment of Prostate Cancer in Kinshasa

  AUTHORS: Dieudonné Molamba Moningo, Junior Konga Liloku, Alpha Tsita Mafuta, Matthieu Nkumu Loposso, Pablo Nkutima Diangienda, Augustin Mongalembe Punga Maole, Richard Koseka Demongawi, Nkodila Aliocha

  KEYWORDS: Deprivation, Prostate Cancer (PCa), Pointe à Pitre Clinic (CPAP)

  JOURNAL NAME: Open Journal of Urology, Vol.11 No.4, April 28, 2021

  ABSTRACT: Context and Objective: Prostate cancer (PCa) is hormone-dependent cancer. In our area, most patients often arrive at the locally advanced stage or the metastatic stage. This justifies the choice of androgen deprivation as the mode of treatment. The objective of this study was to describe the socio-demographic characteristics of patients with PCa. Identifying the period during which the disease remains susceptible to androgen deprivation. Assessing the patient’s prognosis in terms of survival. Methods: This is a retrospective observational study of the course of patients managed for PCa. It involved 51 cases and was conducted at the Pointe à Pitre clinic (CPAP) in Matete Township during a period of 4 years (from March 2014 to June 2018). Results: The mean age of patients was 69.4 ± 9.7 years (40 - 92 years); 39.2% of patients with PCa were aged between 70 - 79 years; 45.1% had consulted for dysuria and 25.5% were hypertensive. All had performed the prostate biopsy, 47.1% were diagnosed at the metastatic stage, with PSA ≥ 100 ng/ml, Gleason scores 8 - 10, and clinical-stage TNM 3 - 4. About 51% were subjected to androcure, 23.5% had been surgically cased and 3.9% had undergone radical prostatectomy. 41.1% had resisted castration within a median of 1.4 years of response to treatment. The median survival was 30 months, with a mean survival of 26.6 months. Conclusion: Prostate cancer involved most of the patients in the age bracket of 70 to 79 years. The diagnosis was performed lately with a high resistance rate of castration and median survival of 30 months.